An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) to participate in fireside chats at Stifel Healthcare Conference on November 14-15, 2023, and Piper Sandler 35th Annual Healthcare Conference on November 28-30, 2023. The management will engage in discussions about the company's initiatives in rare diseases of the immune system, emphasizing its commitment to improving patients' lives. Webcast links provided for both events.
Positive
None.
Negative
None.
BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023.
Stifel Healthcare Conference Date: Tuesday, November 14, 2023 Time: 4:10 PM ET Webcast Link
Piper Sandler 35th Annual Healthcare Conference Date: Tuesday, November 28, 2023 Time: 1:00PM ET Webcast Link
About X4 Pharmaceuticals X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. regulatory approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
What events will X4 Pharmaceuticals be participating in?
X4 Pharmaceuticals will be participating in the Stifel Healthcare Conference on November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference on November 28-30, 2023.
What is the focus of the discussions at the conferences?
The discussions will revolve around the company's initiatives in rare diseases of the immune system and its commitment to improving patients' lives.
Where will the conferences be held?
The Stifel Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference will both be held in New York City.
When will the fireside chats take place?
The fireside chat at the Stifel Healthcare Conference will take place on Tuesday, November 14, 2023, at 4:10 PM ET, and the one at the Piper Sandler 35th Annual Healthcare Conference will take place on Tuesday, November 28, 2023, at 1:00 PM ET.
x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t
